Skip to main content

Table 1 Baseline characteristics and design variables of the including studies

From: Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer

Article Number (M/F)1 C/R/R-S2 Age Mean ± SD3/Median (range) ST4 Cut-off Rate(+)5 Follow up Mean ± SD/Median (range) OM6 Surgery MA7
Sotelo 2014 [24] 472(254/218) 425/47/0 Median:66(31–87) Baseline ≥1/7.5 ml 166/472 Median:40(NR8) OS9; PFS10 YES NO
  472(254/218) 425/47/0 Median:66(31–87) Baseline ≥2/7.5 ml 93/472 Median:40(NR) OS; PFS YES NO
  472(254/218) 425/47/0 Median:66(31–87) Baseline ≥3/7.5 ml 57/472 Median:40(NR) OS; PFS YES NO
  472(254/218) 425/47/0 Median:66(31–87) Baseline ≥5/7.5 ml 34/472 Median:40(NR) OS; PFS YES NO
Seeberg 2014 [25] 194(105/89) 124/70 Median:65(31–93) Baseline ≥1/7.5 ml 37/189 Median:22.5(1–61) OS; PFS 153YES NO
  194(105/89) 124/70 Median:65(31–93) Baseline ≥2/7.5 ml 26/189 Median:22.5(1–61) OS; PFS 153YES YES
  194(105/89) 124/70 Median:65(31–93) Baseline ≥3/7.5 ml 17/189 Median:22.5(1–61) OS; PFS 153YES NO
Gazzaniga 2013 [26] 119(68/51) NR Median:64(29–84) Baseline ≥1/7.5 ml 44/119 Median:12(1–26) PFS NR YES
  119(68/51) NR Median:64(29–84) Baseline ≥3/7.5 ml 24/119 Median:12(1–26) PFS NR YES
Aggarwal 2013 [27] Baseline:209(NR) NR Mean:63.0 ± 12.6 Median: 64 (22–92) Baseline ≥3/7.5 ml 62/209 median: NR(0.2-39.1) OS NR YES
  3-5 W:115(NR) 6-12 W:134(NR) NR NR During-treatment: 3-5 W,6-12 W11 ≥3/7.5 ml 3-5 W: 17/115; 6-12 W: 10/134 NR OS NR YES
Kuboki 2013 [14] 63(34/29) 41/22/0 Median: 61(33–81) Baseline ≥3/7.5 ml 19/63 Median:8.7(NR) OS; PFS NR YES
Deneve 2013 [13] 69(43/26) 66/8/1 Median: 75(38–95) Baseline ≥1/7.5 ml 20/69 Mean:31 ± NR Median:36 (0–52) NR YES NO
Sastre 2012 [28] Baseline:180(118/62) 40/121/19 Median: 65(40–82) Baseline ≥3/7.5 ml 85/180 NR OS; PFS 123YES YES
  Cycle3:147(NR) NR NR Cycle3 ≥3/7.5 ml 23/147 NR OS; PFS 123YES NO
Sato 2012 [29] 25(NR) NR NR Baseline ≥3/7.5 ml 14/25 NR OS M1:NO12 NO
  25(NR) NR NR Baseline ≥1/7.5 ml 18/25 NR OS M1:NO NO
Papavasiliou 2010 [30] 20(13/7) NR Median: 54 (41–81) Baseline During-treatment ≥3/7.5 ml Pre:2/20 intra: 10/20; post: 1/18 Median:11.5 (5–25) OS; PFS YES NO
Tol 2010 [31] 467 (284/183) 225/122/ 120 Median: 63(27–83) Baseline ≥3/7.5 ml Baseline: 129/451 Median: 16.8(NR) OS; PFS NR YES
  1-2 W: 368(NR) 3-5 W:320(NR) 6-12 W:336(NR) 13-20 W: 254(NR) NR Median: 63(27–83) During-treatment: 1-2/3-5/6-12/13-20 W ≥3/7.5 ml 1-2 W: 21/368; 3-5 W: 17/320; 6-12 W: 18/336; 13-20 W: 16/254 NR OS; PFS NR YES
Hiraiwa 2008 [15] 40(NR) NR NR Baseline + During-treatment ≥2/7.5 ml 14/40 NR OS YES YES
  1. 1M/F: Male/female.
  2. 2C/R/R-S: Colon/Rectum/Rectosigmoid.
  3. 3SD: Standard deviation.
  4. 4ST: Sampling time.
  5. 5Rate(+): Rate of CTCs positive patients, n/N.
  6. 6OM: Outcome measured.
  7. 7MA: Multivariance analysis.
  8. 8NR: Not reported.
  9. 9OS: Overall survival.
  10. 10PFS: Progression-free survival.
  11. 11W: Week.
  12. 12M1: Tumor metastasis positive.